Mark Freedman
Affiliations: | Immunology | University of Ottawa, Ottawa, ON, Canada |
Google:
"Mark Freedman"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Jack P. Antel | research scientist | University of Ottawa (Cell Biology Tree) |
Children
Sign in to add trainee| Robert A. Pon | grad student | 2001 | University of Ottawa |
| Zhihong Chen | grad student | 2003-2009 | University of Ottawa |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Freedman MS, Gnanapavan S, Booth RA, et al. (2024) Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management. Ebiomedicine. 101: 104970 |
| Freedman MS, Coyle PK, Hellwig K, et al. (2024) Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives. Neurology and Therapy |
| Cardwell K, Awadia Z, McKenna O, et al. (2023) Physical activity together for MS (PAT-MS): Secondary outcomes of a randomized controlled feasibility trial. Multiple Sclerosis and Related Disorders. 82: 105399 |
| Fakolade A, Awadia Z, Cardwell K, et al. (2023) Physical Activity Together for Multiple Sclerosis (PAT-MS): A randomized controlled feasibility trial of a dyadic behaviour change intervention. Contemporary Clinical Trials Communications. 36: 101222 |
| Singer BA, Arnold DL, Drulovic J, et al. (2023) Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Multiple Sclerosis (Houndmills, Basingstoke, England). 13524585231205708 |
| Sohaei D, Thebault S, Avery LM, et al. (2023) Cerebrospinal fluid camk2a levels at baseline predict long-term progression in multiple sclerosis. Clinical Proteomics. 20: 33 |
| Giovannoni G, Boyko A, Correale J, et al. (2023) A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study. Neurodegenerative Disease Management |
| Kalincik T, Sharmin S, Roos I, et al. (2023) Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis. Jama Neurology. 80: 702-713 |
| Spain RI, Hildebrand A, Waslo CS, et al. (2023) Processing speed and memory test performance are associated with different brain region volumes in Veterans and others with progressive multiple sclerosis. Frontiers in Neurology. 14: 1188124 |
| Jiang T, Ziemssen T, Wray S, et al. (2023) Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis. Cns Drugs |